Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763497 | 0.87 | TP53 (0.49) | TP53CA12CA1CA2CA9 | |
| SCHEMBL1639850 | 0.86 | TP53 (0.51) | TP53CA12CA1CA2CA9 | |
| SCHEMBL19732939 | 0.85 | TP53 (0.47) | TP53CA12CA1CA2CA9 | |
| SCHEMBL4108591 | 0.83 | TP53 (0.45) | TP53CA12CA1CA2CA9 | |
| SCHEMBL17291388 | 0.83 | ALDH1A1 (0.48) | TP53ALDH1A1KMT2AGAAL3MBTL1 | |
| SCHEMBL17291277 | 0.81 | TP53 (0.47) | TP53ALDH1A1KMT2AGAAL3MBTL1 | |
| SCHEMBL4103623 | 0.81 | ALDH1A1 (0.50) | TP53ALDH1A1KMT2AGAAL3MBTL1 | |
| SCHEMBL13848289 | 0.80 | TP53 (0.46) | TP53ALDH1A1KMT2AGAAL3MBTL1 | |
| SCHEMBL17291408 | 0.78 | PKM (0.50) | TP53CA12CA1CA2CA9 | |
| SCHEMBL19732946 | 0.77 | LMNA (0.51) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20090227602-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227602-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227602-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2009-09-10 | — | — | US | disclosed |
| EP-1948168-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | Numerate, Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007051065-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007051065-A2 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227602-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | TP53 3680/4885CA12 4574/4885CA1 3698/4885 |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | TP53 991/4885CA12 3773/4885CA1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.